Next Article in Journal
Antimicrobial, Antioxidant, and Cytotoxic Activities of Ocimum forskolei and Teucrium yemense (Lamiaceae) Essential Oils
Next Article in Special Issue
Dietary Isoflavones and Breast Cancer Risk
Previous Article in Journal
A Population-Based Cohort Study on the Ability of Acupuncture to Reduce Post-Stroke Depression
Previous Article in Special Issue
ShenLingLan Influences the Attachment and Migration of Ovarian Cancer Cells Potentially through the GSK3 Pathway
Article Menu

Export Article

Open AccessReview
Medicines 2017, 4(1), 15; doi:10.3390/medicines4010015

Ganoderma spp.: A Promising Adjuvant Treatment for Breast Cancer

1
Department of Biochemistry, Universidad Central del Caribe, School of Medicine, P.O. Box 60327, Bayamón, PR 00960-6032, USA
2
Department of Science, Pontificia Universidad Católica-Mayagüez, P.O. Box 1326, Mayagüez, PR 00681, USA
3
Department of Neuroscience and Regenerative Medicine, Augusta University, 1120 15th St, Augusta, GA 30912, USA
*
Author to whom correspondence should be addressed.
Academic Editors: Sivarama Vinjamury and Elizabeth Sommers
Received: 29 December 2016 / Revised: 24 February 2017 / Accepted: 3 March 2017 / Published: 15 March 2017
(This article belongs to the Special Issue Complementary and Alternative Medicine for Cancer Patients)
View Full-Text   |   Download PDF [391 KB, uploaded 15 March 2017]   |  

Abstract

For the past several decades, cancer patients in the U.S. have chosen the use of natural products as an alternative or complimentary medicine approach to treat or improve their quality of life via reduction or prevention of the side effects during or after cancer treatment. The genus Ganoderma includes about 80 species of mushrooms, of which several have been used for centuries in traditional Asian medicine for their medicinal properties, including anticancer and immunoregulatory effects. Numerous bioactive compounds seem to be responsible for their healing effects. Among the approximately 400 compounds produced by Ganoderma spp., triterpenes, peptidoglycans and polysaccharides are the major physiologically-active constituents. Ganoderma anticancer effects are attributed to its efficacy in reducing cancer cell survival and growth, as well as by its chemosensitizing role. In vitro and in vivo studies have been conducted in various cancer cells and animal models; however, in this review, we focus on Ganoderma’s efficacy on breast cancers. Evidence shows that some species of Ganoderma have great potential as a natural therapeutic for breast cancer. Nevertheless, further studies are needed to investigate their potential in the clinical setting and to translate our basic scientific findings into therapeutic interventions for cancer patients. View Full-Text
Keywords: Ganoderma; breast cancer; cell death; invasion; migration; metastasis; chemoresistance; natural medicine; NF-κB; PI3K/AKT/mTOR Ganoderma; breast cancer; cell death; invasion; migration; metastasis; chemoresistance; natural medicine; NF-κB; PI3K/AKT/mTOR
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Suárez-Arroyo, I.J.; Loperena-Alvarez, Y.; Rosario-Acevedo, R.; Martínez-Montemayor, M.M. Ganoderma spp.: A Promising Adjuvant Treatment for Breast Cancer. Medicines 2017, 4, 15.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Medicines EISSN 2305-6320 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top